Bibliography

Found 74 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2018
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al..  2018.  Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. Leuk Lymphoma. 59(6):1364-1374.
Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van-Besien K.  2018.  Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.. Leuk Lymphoma. :1-7.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu J-M, Niesvizky R et al..  2018.  Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.. Biol Blood Marrow Transplant. 24(2):288-293.
Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu J-M, Niesvizky R et al..  2018.  Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.. Biol Blood Marrow Transplant. 24(2):288-293.
Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu J-M, Niesvizky R et al..  2018.  Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.. Biol Blood Marrow Transplant. 24(2):288-293.
2017
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A et al..  2017.  Cord blood chimerism and relapse after haplo-cord transplantation.. Leuk Lymphoma. 58(2):288-297.
van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A et al..  2017.  Haplo-cord transplant: HLA-matching determines graft dominance.. Leuk Lymphoma. 58(6):1512-1514.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.